# Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

> **NCT05826366** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 296 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05826366
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-02
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-04-30
- **Target enrollment:** 296 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05826366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05826366, "Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05826366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*